The breadth of the pathways involved explains why BPC-157 is studied across gastrointestinal, musculoskeletal, and neurological recovery models
As of the date and present studies circulating, BPC 157 has few to no side effects
ChromaDex 2024 medRxiv) show IV delivery raises NAD+ rapidly
Over 250 pounds (113kg+): Maximum standard dosing of 500mcg applies, though some individuals may benefit from extending cycle length rather than increasing dose
This combination is used to explore multi-pathway peptide signalling, molecular binding dynamics and cellular response patterns within preclinical research environments
Numbness and tingling in the hands and feet, depression, confusion, or poor memory can also occur